{"slideshow_credits": null, "snippet": "Government has no real tools to curb extortionate prices....", "abstract": "Op-Ed article by Elisabeth Rosenthal points to controversy surrounding Mylan's increase of prices on EpiPen auto-injectors as example of how federal government has no tools with which to regulate pharmaceutical industry's pricing practices; result is often prohibitive consumer costs for life-saving drugs.", "section_name": "Opinion", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Elisabeth", "role": "reported", "lastname": "ROSENTHAL", "rank": 1, "organization": ""}], "original": "By ELISABETH ROSENTHAL"}, "web_url": "http://www.nytimes.com/2016/09/04/opinion/sunday/the-lesson-of-epipens-why-drug-prices-spike-again-and-again.html", "lead_paragraph": "Government has no real tools to curb extortionate prices.", "headline": {"print_headline": "Old Drug, Pricey New Package", "main": "The Lesson of EpiPens: Why Drug Prices Spike, Again and Again", "content_kicker": "Opinion", "kicker": "Opinion"}, "_id": "57c9b2b395d0e021d79841ab", "word_count": "1217", "multimedia": [{"height": 126, "url": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 440, "url": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "440"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/04/opinion/sunday/04rosenthal/04rosenthal-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-09-04T04:00:00+0000", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"name": "subject", "value": "Medical Devices", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Epinephrine (Drug)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Trademarks and Trade Names", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Mylan Inc", "is_major": "Y", "rank": "6"}, {"name": "persons", "value": "Bresch, Heather", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": "Sunday Review", "type_of_material": "Op-Ed"}